MIRA-1 is a maleimide-derived small molecule that reactivates the tumor suppressor function of mutant p53, inducing apoptosis in several human solid tumor cell lines carrying tetracycline-regulated mutant p53 (IC50 = 10 μM in vitro).1 Treatment of tumor cells with MIRA-1 induces p21, MDM2 and PUMA in a mutant p53-dependent manner.[1] At a concentration of 5-10 mg/kg, MIRA-1, alone or in combination with dexamethasone , arrested tumor growth in a mouse xenograft model of multiple myeloma.[2]

Reference:
[1]. Bykov, V.J.N., Issaeva, N., Zache, N., et al. Reactivation of mutant p53 and induction of apoptosis in human tumor cells by maleimide analogs. The Journal of Biological Chemisty 280(34), 30384-30391 (2005).
[2]. Saha, M.N., Chen, Y., Chen, M.H., et al. Small molecule MIRA-1 induces in vitro and in vivo anti-myeloma activity and synergizes with current anti-myeloma agents. British Journal of Cancer 110(9), 2224-2231 (2014).